Effect of High-Intensity Interval Training Versus Home-Based Rehabilitation Program On Patients Underwent Coronary Artery Bypass Graft Surgery

August 18, 2026 updated by: Mohammed Obaid Almuzaini, Kafrelsheikh University

Effect of High-Intensity Interval Training Versus Home-Based Rehabilitation Program on Peak Metabolic Equivalents On Patients Underwent Coronary Artery Bypass Graft Surgery

  1. To assess the effect of high-intensity interval training on peak metabolic equivalents in patients with coronary heart disease after the coronary artery bypass grafting surgery.
  2. To assess the effect of a home-based cardiac rehabilitation program on peak metabolic equivalents in patients with coronary heart disease after coronary artery bypass grafting surgery.
  3. To compare functional outcomes between the different treatment approaches.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Cardiovascular disease (CVD), a leading cause of death in the U.S., is primarily driven by coronary artery disease (CAD), which accounts for 85% of related fatalities. The Coronary Artery Bypass Grafting (CABG) procedure, used to treat blocked arteries, can lead to complications like reduced cardiopulmonary function and decreased physical activity post-surgery. To combat these issues, cardiac rehabilitation (CR) is recommended, incorporating exercise, dietary changes, and stress reduction. Research indicates that CR, particularly high-intensity interval training (HIIT), is safe for coronary artery disease patients and effectively enhances cardiopulmonary fitness. Maintaining exercise capacity is critical as it significantly correlates with improved survival rates in Cardiovascular disease patients. Despite evidence supporting cardiac rehabilitation's benefits, participation rates remain low, highlighting a need for sustained exercise habits post-rehabilitation. Home-based CR has shown effectiveness comparable to outpatient programs, although long-term benefits remain uncertain due to insufficient follow-up studies.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
84

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Participants will be eligible if they are clinically stable as defined by the American College of Cardiology/American Heart Association.
  2. Only Participants will be stratified as low to moderate risk as identified by the American College of Sport Medicine/
  3. Mean age ± standard deviation, 55 ± 3 years.
  4. All patients underwent coronary artery bypass graft surgery, rested at home for at least one month, and then returned to the center for a cardiac rehabilitation program

Exclusion Criteria:

  1. Patients will be excluded from this study if they had an ejection fraction of less than 40% at rest (high risk as defined by American Association of Cardiovascular and Pulmonary Rehabilitation Stratification).
  2. Mental health disorders (such an anxiety or depression).
  3. Any vision or hearing defects or any neurological, respiratory, or musculoskeletal conditions that have an impact on ambulation.
  4. Irreversible heart failure.
  5. Myocardial Infarction (MI) over the past month.
  6. Persistent ventricular arrhythmias or unstable angina.
  7. Any exercise restrictions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: High Intensity Interval Training program
Twenty-eight patients will receive a high-intensity interval training program for four weeks
Other: High Intensity Interval Training program
High-Intensity Interval Training (HIIT) includes a 5-minute warm-up, followed by a 3-minute training session at 60% to 70% of heart rate reserve and four 4-minute high-intensity intervals at 80% to 90% of heart rate reserve. Each interval is followed by a 3-minute active recovery at 60% to 70% of heart rate reserve, concluding with a 4-minute cool-down. Subjects without balance or leg issues performed treadmill exercises, while those with such complaints used a leg ergo-cycle.
Experimental: home-based cardiac rehabilitation intervention
Twenty-eight patients will receive a home-based cardiac rehabilitation intervention for four weeks
Other: home-based cardiac rehabilitation intervention
The home-based cardiac rehabilitation program utilizes Physio-tools software for exercise management. Participants will receive a data sheet for exercise logging, a color-coded program, and a Polar watch. Weekly phone support will provide encouragement and answer questions. The program involves moderate-intensity exercises, 3 times a week, including circuit training for 45 minutes, with structured warm-up, aerobic, and cool-down phases.
Active Comparator: no intervention
all participants will be given an instruction booklet that contains instructions and precautions about surgery, wound care and encouragement to be active.
Other: no intervention program
The control group had no intervention program. Based on current standard practice, all participants will be given an instruction booklet that contains instructions and precautions about surgery, wound care and encouragement to be active.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
assessment of Exercise capacity
Time Frame: At baseline and after 4 weeks
Exercise capacity will be evaluated through a symptom-limited graded treadmill exercise test following the Bruce protocol, starting at 1.7 mph and a 10% incline. The intensity will increase every 3 minutes until the participant reaches exhaustion or meets clinical termination criteria. Capacity will be measured in metabolic equivalents (METs), with peak metabolic equivalents calculated based on the highest workload achieved. Estimated oxygen consumption will be expressed in mL·kg-¹·min-¹ and converted to METs. The main outcome will be the change in peak metabolic equivalents from baseline to post-intervention assessment.
At baseline and after 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Kafrelsheikh University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 28, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 18, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 20, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 18, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Mohamed_Msc

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings